EC approves Rybrevant with Lazcluze for advanced lung cancer - PharmaTimes New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC

#Rybrevant #amivantamab #Lazcluze #lazertinib #advancedlungcancer #lungcancer #EGFRmutatedNSCLC #JanssenCilagInternational #advancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #thoraciccancer #EGFRmutationpositiveNSCLC #precisionmedicine #MARIPOSAstudy
pharmatimes.com/news/europea...